KCNK3 and cardiac rhythm disease: Both NaV1.5 and TASK-1 are attractive drug targets in particular for the development of treatments of atrial fibrillation, the most common cardiac arrhythmia (Sossalla et al., 2010; Wiedmann et al., 2021).